<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>How Is ResMed&#x27;s Stock Performance Compared to Other Healthcare Stocks? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">How Is ResMed&#x27;s Stock Performance Compared to Other Healthcare Stocks?</h2>
    <div class="badge">2025-09-15T06:07:58+00:00</div>
    <ul>
      <li>Further, its non-GAAP EPS soared 22.6% year-over-year to $2.55, exceeding the consensus estimates by 3.7%.</li>
<li>RMD’s mean price target of $289.25 suggests a 7.1% upside potential from current price levels.</li>
<li>ResMed’s overall net revenues for the quarter grew 10.2% year-over-year to $1.35 billion, surpassing the Street expectations by 1.9%.</li>
<li>22 and is currently trading 8.1% below that peak.</li>
<li>ResMed’s stock prices gained 2.7% in the trading session following the release of its impressive Q4 results on Jul.</li>
<li>Moreover, ResMed has also significantly outperformed its peer, Becton, Dickinson and Company’s (BDX) 17.6% decline in 2025 and 20.7% plunge over the past 52 weeks.</li>
<li>RMD stock prices have surged 18.1% in 2025 and 7.8% over the past 52 weeks, outpacing XLV’s marginal 39 bps uptick on a YTD basis and 11.4% decline over the past year.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=How Is ResMed&amp;#x27;s Stock Performance Compared to Other Healthcare Stocks?\n• Further, its non-GAAP EPS soared 22.6% year-over-year to $2.55, exceeding the consensus estimates by 3.7%.\n• RMD’s mean price target of $289.25 suggests a 7.1% upside potential from current price levels.\n• ResMed’s overall net revenues for the quarter grew 10.2% year-over-year to $1.35 billion, surpassing the Street expectations by 1.9%.\n• 22 and is currently trading 8.1% below that peak.\n• ResMed’s stock prices gained 2.7% in the trading session following the release of its impressive Q4 results on Jul.\n• Moreover, ResMed has also significantly outperformed its peer, Becton, Dickinson and Company’s (BDX) 17.6% decline in 2025 and 20.7% plunge over the past 52 weeks.\n• RMD stock prices have surged 18.1% in 2025 and 7.8% over the past 52 weeks, outpacing XLV’s marginal 39 bps uptick on a YTD basis and 11.4% decline over the past year." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/m/18e5adce-bfb3-30fe-a075-7f55ac01f1bc/how-is-resmed%27s-stock.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>